TY - JOUR
T1 - Association between convalescent plasma and the risk of mortality among patients with COVID-19
T2 - A meta-analysis
AU - Wardhani, Shinta Oktya
AU - Fajar, Jonny Karunia
AU - Wulandari, Laksmi
AU - Soegiarto, Gatot
AU - Purnamasari, Yeni
AU - Asmiragani, Anisa
AU - Maliga, Helnida Anggun
AU - Ilmawan, Muhammad
AU - Seran, Gloriana
AU - Iskandar, Dheka Sapti
AU - Ndapa, Conchita Emiliana
AU - Hamat, Viviana
AU - Wahyuni, Rafika Ajeng
AU - Cyntia, Linda Oktaviana Suci
AU - Maarang, Feronika Maryanti
AU - Beo, Yosef Andrian
AU - Adar, Olivera Agnes
AU - Rakhmadhan, Iraky Mardya
AU - Shantikaratri, Emilia Tiara
AU - Putri, Ayu Sekarani Damana
AU - Wahdini, Rizqa
AU - Broto, Endang Pati
AU - Suwanto, Agnes Wanda
AU - Tamara, Fredo
AU - Mahendra, Aditya Indra
AU - Winoto, Eden Suryoiman
AU - Krisna, Pratista Adi
AU - Harapan, Harapan
N1 - Publisher Copyright:
© 2021 Wardhani SO et al.
PY - 2021
Y1 - 2021
N2 - Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non - RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients.
AB - Background: Convalescent plasma (CCP) has been used for treating some infectious diseases; however, the efficacy of CCP in coronavirus disease 2019 (COVID-19) remains controversial. The aim of this research was to assess the efficacy of CCP as an adjunctive treatment in COVID-19 patients. Methods: Embase, PubMed, Web of Science, Cochrane and MedRix were searched for potentially relevant articles. All included papers were assessed for the quality using modified Jadad scale and Newcastle-Ottawa scale for randomized controlled trial (RCT) and non - RCT, respectively. We used a Q test and Egger test to assess the heterogeneity and publication bias among studies, respectively. Mortality rates between patients treated with standard treatment and standard treatment with CCP were compared using a Z test. Results: A total of 12 papers consisting of three cross-sectional studies, one prospective study, five retrospective studies, and three RCT studies were included in our analysis. Of them, a total of 1,937 patients treated with CCP and 3,405 patients without CCP were included. The risk of mortality was 1.92-fold higher in patients without CCP compared to patients treated with CCP (OR: 1.92; 95%CI: 1.33, 2.77; p=0.0005). In severe COVID-19 sub-group analysis, we found that patients without CCP had a 1.32 times higher risk of mortality than those treated with CCP (OR: 1.32; 95%CI: 1.09, 1.60; p=0.0040). Conclusions: CCP, as adjunctive therapy, could reduce the mortality rate among COVID-19 patients.
KW - COVID-19
KW - Convalescent plasma
KW - Mortality
KW - Outcomes
KW - Passive immunization
UR - http://www.scopus.com/inward/record.url?scp=85107586864&partnerID=8YFLogxK
U2 - 10.12688/f1000research.36396.3
DO - 10.12688/f1000research.36396.3
M3 - Article
C2 - 34136130
AN - SCOPUS:85107586864
SN - 2046-1402
VL - 10
JO - F1000Research
JF - F1000Research
M1 - 64
ER -
